glucose, (beta-d)-isomer has been researched along with Cruveilhier-Baumgarten Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Brand, S; Gerbes, AL; Gmelin, L; Göke, B; Pfeiler, S; Schewe, J; Steib, CJ | 1 |
Garcia-Tsao, G; Saffo, S; Taddei, T | 1 |
2 other study(ies) available for glucose, (beta-d)-isomer and Cruveilhier-Baumgarten Syndrome
Article | Year |
---|---|
Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension.
Topics: Animals; Anti-Inflammatory Agents; Cannabinoid Receptor Agonists; Cannabinoids; Heme Oxygenase (Decyclizing); Hypertension, Portal; Indenes; Kupffer Cells; Lipopolysaccharides; Male; Molecular Targeted Therapy; Portal Pressure; PPAR alpha; Pyrazoles; Rats; Receptor, Cannabinoid, CB2; Thromboxane B2; Zymosan | 2013 |
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Outcome Assessment, Health Care; Polyuria; Sodium-Glucose Transporter 2 Inhibitors; Tertiary Care Centers; Urinary Tract Infections; Young Adult | 2021 |